Conţinutul numărului revistei |
Articolul precedent |
Articolul urmator |
940 3 |
Ultima descărcare din IBN: 2020-03-26 12:53 |
SM ISO690:2012 DIACONU, Nadejda. Antithrombotic Treatment of Patients with Atrial Fibrillation and Ischemic Stroke. In: Curierul Medical, 2011, nr. 3(321), pp. 26-31. ISSN 1875-0666. |
EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
Curierul Medical | ||||||
Numărul 3(321) / 2011 / ISSN 1875-0666 | ||||||
|
||||||
Pag. 26-31 | ||||||
|
||||||
Descarcă PDF | ||||||
Rezumat | ||||||
Objective: Assessment of the use of oral anticoagulants in patients with ischemic stroke and atrial fibrillation in the Republic of Moldova. Methods: A
retrospective study of all patients hospitalized with stroke during one-year period in a municipal hospital. Results: Out of 735 patients with ischemic stroke,
atrial fibrillation was noted in 28.4% (206/189). The majority were female, 57.8% (119/206) with the mean age of 70.1 ± 0.65 years. Ninety two (92.5%) of
all patients had a high thromboembolic risk, 5.8% - medium and 1% - low risks. In the medium risk group the rate of antithrombotic treatment represented
88.9%. Even if about 92% were considered to have a high risk for thromboembolic complications, 60% were eligible for anticoagulation, but only 7.1%
received it prior to the stroke. After the cerebrovascular accident all patients were considered to be at high risk, but only 14.8% were anticoagulated and
only 26.6% (4/15) had the therapeutic International Normalized Ratio (INR) in the range 2.0-3.0. Physical disability and non-compliance were the most
frequent reasons for noncompliance to anticoagulation. At the next visit 65.2% were receiving aspirin, and 20% were not receiving any antithrombotic
medication. No hemorrhagic complications were reported after 14 months of follow up. Conclusions: A significant proportion of patients (92.9%) with
atrial fibrillation and high antithrombotic risk were not anticoagulated before ischemic stroke for various reasons: underestimation of antithrombotic
benefit and fear of hemorrhagic complications from physician’s behalf and difficulties in systematic INR monitoring from patient’s behalf. |
||||||
Cuvinte-cheie atrial fibrillation, ischemic stroke, antithrombotic treatment |
||||||
|